|
Chimeric Antigen Receptor T-Cell Therapy Clinical Trials
7 actively recruiting trials across 5 locations
Also known as: Axi-Cel, CAR T Infusion, CAR T Therapy, CAR T-cell Therapy, Chimeric Antigen Receptor T-cell Infusion +1 more
Pipeline
Early 1: 1Phase 1: 2Phase 2: 4
Top Sponsors
- City of Hope Medical Center2
- University of Washington1
- Mehrdad Abedi, MD1
- Mayo Clinic1
- Joseph Tuscano1
Indications
- Cancer7
- Refractory Diffuse Large B-Cell Lymphoma4
- Recurrent Diffuse Large B-Cell Lymphoma4
- Refractory Primary Mediastinal Large B-Cell Lymphoma2
- Refractory Grade 3b Follicular Lymphoma2
Duarte, California2 trials
Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma
City of Hope Medical Center
Early 1
Sacramento, California2 trials
Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
University of California Davis Comprehensive Cancer Center
Phase 1
Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy
University of California Davis Comprehensive Cancer Center
Phase 2
Scottsdale, Arizona1 trial
Tampa, Florida1 trial
Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL
Moffitt Cancer Center
Phase 2
Seattle, Washington1 trial
Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T
Fred Hutch/University of Washington Cancer Consortium
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.